{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:06:09Z","timestamp":1754111169045,"version":"3.40.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Technology Assessment","award":["NIHR129720"],"award-info":[{"award-number":["NIHR129720"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Post herpetic neuralgia (PHN) is the most common complication of herpes zoster, also known as shingles. Amitriptyline has been postulated to prevent PHN. The objective is to determine whether prophylactic low-dose amitriptyline prevents PHN in patients newly diagnosed with shingles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a multicentre, individually randomized, pragmatic, placebo-controlled superiority trial with health economic analysis and nested qualitative study. Patients with new-onset shingles are screened by treating clinicians in participating general practitioner surgeries. Key eligibility criteria are age \u226550\u2005years, \u22646\u2005days since rash onset and not already taking (and no contraindication to) amitriptyline. Participants are randomized 1:1 to amitriptyline 10\u2005mg or matched placebo tablets (dose escalated as tolerated to a maximum of three tablets daily for 70\u2005days). Resource-use data (including health, social and informal care, personal expenses and usual activities) are collected from electronic medical records and participant questionnaires. A sample of recruitment conversations are audio-recorded and interviews conducted with recruiters and patients, including those who decline to participate or who withdraw from the trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The primary outcome is the presence of PHN (\u22653\/10 worst pain on Zoster Brief Pain Inventory) at 90\u2005days after rash onset. Primary health economic analyses will present cost per case of PHN prevented and cost per quality-adjusted life year. Qualitative data will be analysed to optimize trial delivery and to aid interpretation and implementation of the trial findings. This is the largest trial to date to evaluate the clinical\/cost-effectiveness and acceptability of prophylactic low-dose amitriptyline for the prevention of PHN.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Protocol registration<\/jats:title>\n                  <jats:p>EudraCT 2021-001101-78 and ISRCTN14490832.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/skinhd\/vzaf002","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T17:01:37Z","timestamp":1739552497000},"page":"1-8","source":"Crossref","is-referenced-by-count":1,"title":["Amitriptyline for the prevention of post herpetic neuralgia: study protocol for the ATHENA study"],"prefix":"10.1093","volume":"5","author":[{"given":"Sian","family":"Wells","sequence":"first","affiliation":[{"name":"Bristol Trials Centre, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie J","family":"MacNeill","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Gilbertson","sequence":"additional","affiliation":[{"name":"Centre for Applied Excellence in Skin & Allergy Research, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazel","family":"Everitt","sequence":"additional","affiliation":[{"name":"Primary Care Research Centre, University of Southampton , Southampton ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"van\u00a0Hecke","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, Ghent University , Ghent ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Banks","sequence":"additional","affiliation":[{"name":"NIHR Applied Research Collaborative West (NIHR ARC West), University Hospitals Bristol NHS Foundation Trust , Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Rees","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Kandiyali","sequence":"additional","affiliation":[{"name":"Centre for Health Economics Warwick (CHEW), Warwick Medical School, University of Warwick , Warwick ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty","family":"Garfield","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorelei","family":"Hunt","sequence":"additional","affiliation":[{"name":"Centre for Applied Excellence in Skin & Allergy Research, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Fodor","sequence":"additional","affiliation":[{"name":"Centre for Applied Excellence in Skin & Allergy Research, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikki","family":"Wylde","sequence":"additional","affiliation":[{"name":"Musculoskeletal Research Unit, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Johnson","sequence":"additional","affiliation":[{"name":"School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair D","family":"Hay","sequence":"additional","affiliation":[{"name":"Centre for Academic Primary Care, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony\u00a0E","family":"Pickering","sequence":"additional","affiliation":[{"name":"School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-8823","authenticated-orcid":false,"given":"Matthew J","family":"Ridd","sequence":"additional","affiliation":[{"name":"Centre for Applied Excellence in Skin & Allergy Research, University of Bristol, Bristol ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2025031806235316800_vzaf002-B1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2334-13-170","article-title":"Similar herpes zoster incidence across Europe: results from a systematic literature review","volume":"13","author":"Pinchinat","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2025031806235316800_vzaf002-B2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1477-7525-12-92","article-title":"Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the zoster quality of life (ZQOL) study","volume":"12","author":"Serpell","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"2025031806235316800_vzaf002-B3","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.pain.2013.04.015","article-title":"Natural history of herpes zoster: late follow-up of 3.9 years (n = 43) and 7.7 years (n = 10)","volume":"154","author":"Reda","year":"2013","journal-title":"Pain"},{"key":"2025031806235316800_vzaf002-B4","doi-asserted-by":"crossref","first-page":"e0170653","DOI":"10.1371\/journal.pone.0170653","article-title":"Chronic pain, depression and cardiovascular disease linked through a shared genetic predisposition: analysis of a family-based cohort and twin study","volume":"12","author":"van Hecke","year":"2017","journal-title":"PLOS ONE"},{"key":"2025031806235316800_vzaf002-B5","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Clinical practice. Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N Engl J Med"},{"key":"2025031806235316800_vzaf002-B6","first-page":"CD006866","article-title":"Antiviral treatment for preventing postherpetic neuralgia","volume":"2014","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025031806235316800_vzaf002-B7","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(06)68032-X","article-title":"The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial","volume":"367","author":"van Wijck","year":"2006","journal-title":"Lancet"},{"key":"2025031806235316800_vzaf002-B8","doi-asserted-by":"crossref","first-page":"e0217335","DOI":"10.1371\/journal.pone.0217335","article-title":"Efficacy of gabapentin for the prevention of postherpetic neuralgia in patients with acute herpes zoster: a double blind, randomized controlled trial","volume":"14","author":"Bulilete","year":"2019","journal-title":"PLOS ONE"},{"key":"2025031806235316800_vzaf002-B9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/cid\/ciad714","article-title":"PROCESS trial: effect of duloxetine premedication for postherpetic neuralgia within 72 h of herpes zoster reactivation-a randomized controlled trial","volume":"78","author":"Zhao","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025031806235316800_vzaf002-B10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.chembiol.2009.05.010","article-title":"Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA\/TrkB heterodimerization and has potent neurotrophic activity","volume":"16","author":"Jang","year":"2009","journal-title":"Chem Biol"},{"key":"2025031806235316800_vzaf002-B11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0885-3924(97)00077-8","article-title":"The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Bowsher","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"2025031806235316800_vzaf002-B12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s13063-017-2284-x","article-title":"Impact of a deferred recruitment model in a randomised controlled trial in primary care (CREAM study)","volume":"18","author":"Shepherd","year":"2017","journal-title":"Trials"},{"key":"2025031806235316800_vzaf002-B13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2125.1999.00973.x","article-title":"Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline","volume":"48","author":"Gupta","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"2025031806235316800_vzaf002-B14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","article-title":"Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory","volume":"5","author":"Coplan","year":"2004","journal-title":"J Pain"},{"key":"2025031806235316800_vzaf002-B15","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2025031806235316800_vzaf002-B16","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"2025031806235316800_vzaf002-B17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"2025031806235316800_vzaf002-B18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jamda.2009.11.003","article-title":"The Tilburg frailty indicator: psychometric properties","volume":"11","author":"Gobbens","year":"2010","journal-title":"J Am Med Dir Assoc"},{"key":"2025031806235316800_vzaf002-B19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cct.2003.10.016","article-title":"Assessment of blinding in clinical trials","volume":"25","author":"Bang","year":"2004","journal-title":"Control Clin Trials"},{"key":"2025031806235316800_vzaf002-B20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12913-021-06364-w","article-title":"Development of a brief, generic, modular resource-use measure (ModRUM): cognitive interviews with patients","volume":"21","author":"Garfield","year":"2021","journal-title":"BMC Health Serv Res"},{"author":"Sealed Envelope Ltd","key":"2025031806235316800_vzaf002-B21"},{"key":"2025031806235316800_vzaf002-B22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0976-500X.72352","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"1","author":"Schulz","year":"2010","journal-title":"J Pharmacol Pharmacother"},{"key":"2025031806235316800_vzaf002-B23","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"author":"National Institute for Health and Care Excellence","key":"2025031806235316800_vzaf002-B24"},{"key":"2025031806235316800_vzaf002-B25","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1049732315617444","article-title":"Sample size in qualitative interview studies: guided by information power","volume":"26","author":"Malterud","year":"2016","journal-title":"Qualitat Health Res"},{"author":"MHRA","key":"2025031806235316800_vzaf002-B26"},{"key":"2025031806235316800_vzaf002-B27","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"2025031806235316800_vzaf002-B28","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term \u00adpersistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025031806235316800_vzaf002-B29","doi-asserted-by":"crossref","first-page":"e037458","DOI":"10.1136\/bmjopen-2020-037458","article-title":"Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study","volume":"10","author":"Andrews","year":"2020","journal-title":"BMJ Open"},{"key":"2025031806235316800_vzaf002-B30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025031806235316800_vzaf002-B31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/j.pain.0000000000000307","article-title":"A systematic review and meta-analysis of risk factors for postherpetic neuralgia","volume":"157","author":"Forbes","year":"2016","journal-title":"Pain"},{"key":"2025031806235316800_vzaf002-B32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"volume-title":"The Brief Pain Inventory User Guide","year":"2009","author":"Cleeland","key":"2025031806235316800_vzaf002-B33"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/1\/1\/61899985\/vzaf002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/1\/1\/61899985\/vzaf002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T06:24:29Z","timestamp":1742279069000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/5\/1\/1\/8015676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzaf002","relation":{},"ISSN":["2690-442X"],"issn-type":[{"type":"electronic","value":"2690-442X"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]}}}